IPHA News and Press, Innate Pharma S.A.

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate...

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2026 financial calendar: March 26, 2026 : Publication of 2025 financial statements May 13, 2026 : Publication of reven...

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of its executive team will participate in one-on-one meetings...

2025-11-13 17:21:36 ET Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Jonathan Dickinson - CEO & Director Sonia ...

2025-11-13 06:32:53 ET More on Innate Pharma Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript Innate Pharma S.A. (IPHA) Analyst/Investor Day - Slideshow Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dos...